View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
In association with Cytiva for Cell & Gene Therapy coverage
  1. News
July 15, 2021

CTI Clinical Trial and Consulting Services acquires Dynakin

CTI expects the deal to create a global full-service clinical research organisation.

CTI Clinical Trial and Consulting Services (CTI) has acquired contract research organisation (CRO) Dynakin, which offers model-driven drug development services.

Dynakin operates a bio lab with 20 years of experience and domestic capabilities across Europe.

CTI intends to boost laboratory services for supporting rare disease and cell and gene therapy research worldwide. The company is setting up a lab in Cincinnati, Ohio, US, and will cover the Americas.

The addition of Dynakin’s laboratory services is expected to cover Europe and the Middle East and Africa (MEA) region.

Furthermore, the drug modelling or pharmacometrics services of Dynakin will support CTI’s Regulatory and Scientific Affairs unit.

These services support and/or validate dosing and regulatory decisions at all development stages, as well as allow the optimal design of clinical trials, CTI said.

CTI will combine the CRO services of Dynakin with its European clinical team. The merger is anticipated to result in a strong global full-service clinical research organisation.

Dynakin’s co-founders Dr Monica Rodriguez and Dr Nerea Leal will be appointed to new roles in CTI to support its growth.

CTI chairman and CEO Timothy Schroeder said: “Dynakin and CTI share common philosophies and cultures, with a focus on teamwork, employee retention and career development.

“We are passionate about continued growth and expansion for the continued success of the company, so this acquisition is a great fit for the next phase of growth at CTI.”

The companies did not disclose the financial terms of the acquisition.

Earlier this month, the EQT IX fund (EQT Private Equity) and Goldman Sachs Asset Management’s Private Equity business agreed to acquire a CRO, Parexel, from Pamplona Capital Management for $8.5bn.

Separately, clinical trial software firm Castor has raised $45m in a Series B financing round led by Eight Roads Ventures and F-Prime Capital, and joined by current investors Two Sigma Ventures and Inkef Capital.

The new financing takes Castor’s total funding to $65m. The proceeds will be used to support product development, especially to scale up direct-to-patient trials.

Castor developed a self-service clinical research platform that researchers can use to design studies and incorporate data from all types of sources in real-time. Patients can self-enrol, consent and share their data.

Cell & Gene Therapy Coverage on Clinical Trials Arena supported by Cytiva.

Editorial content is independently produced and follows the highest standards of journalistic integrity. Topic sponsors are not involved in the creation of editorial content.

Free Whitepaper

Secure the cell therapy supply chain from bench to bedside

The development of cell therapies is changing healthcare, delivering new hope to thousands of patients around the world. The vein-to-vein workflow for these therapies, however, is not without challenges, many of which will increase as we scale up to treat more patients. Download this free guide from Cytiva to learn more about the challenges and risks associated with the cryogenic supply chain for cell therapies, and how supply chain disruptions can best be mitigated.
by Cytiva Thematic

By clicking the Download Free Whitepaper button, you accept the terms and conditions and acknowledge that your data will be used as described in the Cytiva Thematic privacy policy By downloading this Whitepaper, you acknowledge that we may share your information with our white paper partners/sponsors who may contact you directly with information on their products and services.

Visit our privacy policy for more information about our services, how we may use, process and share your personal data, including information on your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Topics in this article:
NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy


Thank you for subscribing to Clinical Trials Arena